Further Evidence of von Willebrand Factor Involvement in Thrombotic Thrombocytopenia Purpura

Summary

Fourteen patients diagnosed as having thrombotic thrombocytopenia purpura (TTP) were studied. Those who survived have been followed during a 1 to 7 year period. The clinical diagnosis was based on changing neurological findings, thrombocytopenia and evidence of microangiopathic hemolytic anemia. Laboratory tests included the determination of von Willebrand factor antigen (VWF:Ag), ristocetin cofactor (RiCof) and the electrophoretic mobility of von Willebrand factor (CIE VWF:Ag). The ratio of RiCof to VWF:Ag was then calculated. Control individuals included healthy subjects and patients with thrombocytopenia of several etiologies. Statistical differences between the values of RiCof, the ratio of RiCof : VWF: Ag and the CIE of VWF: Ag were found for samples comparing active disease and remission phase. The recovery from thrombocytopenia paralleled the correction of abnormal parameters. Similarly, significant differences were found when above parameters were compared between thrombocytopenia of TTP with other thrombocytopenic states. We suggest that these abnormal tests could be useful in distinguishing TTP from other disorders, and may have prognostic significance in patients already diagnosed as having TTP.

Key words

Thrombotic thrombocytopenia purpura (TTP) - von Willebrand factor antigen (VWF : Ag) - Ristocetin cofactor (RiCof)

• References

• 1 Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Arch Intern Med 1925; 36: 89-93
• 2 Berkowitz IR, Daldorf FG, Blatt PM. Thrombotic thrombocytopenic purpura. A pathology review J Am Med Assoc 1979; 241: 1709-1720
• 3 Byrnes KK, Lian EC-Y. Recent therapeutic advances in thrombotic thrombocytopenic purpura. Semin Thromb Hemostas 1979; 5: 199-215
• 4 Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977; 50: 413-417
• 5 Machin SJ. Clinical annotation. Thrombotic thrombocytopenic purpura Br J Haematol 1984; 56: 191-197
• 6 Berns ER, Zucker-Franklin D. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood 1982; 60: 1030-1037
• 7 Chen YC, McLeod B, Hall ER, Wu KK. Accelerated prostacyclin degradation in thrombotic thrombocytopenic purpura. Lancet 1981; 2: 267-269
• 8 Siddiqui FA, Lian EC-Y. Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma. J Clin Invest 1985; 76: 1330-1337
• 9 Kelton JG, Moore J, Santos A, Sheridan D. Detection of a platelet-agglutinating factor in thrombotic thrombocytopenic purpura. Ann Intern Med 1984; 101: 589-593
• 10 Moake JL, Rudy CK, Troll JH. et al Usually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1433
• 11 Brecher G, Cronkite EP. Morphology and enumeration of human blood platelets. J Appl Physiol 1950; 3: 365-377
• 12 Chediak J, Maxey B, Telfer M. Determination of factor VIII related antigen using commercial antisera. Am J Clin Pathol 1977; 67: 462-469
• 13 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
• 14 Sultan I, Simeon J, Caen JP. Electrophoretic heterogeneity of normal factor VIII/von Willebrand protein, and abnormal electrophoretic mobility in patients with von Willebrand’s disease. J Lab Clin Med 1976; 87: 185-197
• 15 Weiss HJ, Rogers J, Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand’s disease and its correction by factor VIII. J Clin Invest 1973; 52: 2697-2707
• 16 Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand’s disease subtypes. Blood 1982; 59: 1272-1278
• 17 Glas-Greenwalt PI A, Hall JM, Panke TW, Kant KS, Allen CM, Poliak VE. Fibrinolysis in health and disease: Abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura. J Lab Clin Med 1986; 108: 415-422
• 18 Bukowski RM, Hewlett JS, Reimer RR, Groppe CW, Weick JK, Livingston RB. Therapy of thrombotic thrombocytopenic purpura: An overview. Semin Thromb Hemostas 1981; 7: 1-8
• 19 Remuzzi G. Thrombotic thrombocytopenia purpura and allied disorders. In: Thrombosis and Hemostasis. Verstrate M, Vermylen J, Lijnen HR, Arnout J. (eds) Leuven University Press; Leuven: 1987
• 20 Moake JL, Tang SS, Olson JD, Troll JH, Cimo PL, Davies PJ A. Platelet von Willebrand factor, and prostaglandin I₂ . Am J Physiol 1981; 241: 454-459
• 21 Fitzgerald GA, Maas RL, Stein R, Oates JH, Roberts LJ. Intravenous prostacyclin in thrombotic thrombocytopenic purpura. Ann Intern Med 1981; 95: 319-321
• 22 Remuzzi G, Zoja C, Rossi E. Prostacyclin in thrombotic microangiopathy. Semin Hematol 1987; 24: 110-118